Key Takeaways & Executive Findings
- •• Correction of a concentration error in the preconditioning step of the atrial cardiomyocyte differentiation protocol, changing from 1 ng/mL to 2 ng/mL. • Ensures reproducibility and accuracy of the published protocol for generating atrial cardiomyocytes from induced pluripotent stem cells. • Important for researchers modeling atrial arrhythmias, as precise cytokine concentrations are critical for successful differentiation. • Highlights the importance of rigorous error correction in scientific literature to maintain research integrity.
Abstract
The original article presents an error in Figure 1A—for the Preconditioning step, the text ‘1ng/mL’ should instead state ‘2ng/mL’.
1. Introduction
This correction notice addresses an error identified in the original article titled 'Development of a robust induced pluripotent stem cell atrial cardiomyocyte differentiation protocol to model atrial arrhythmia' published in Stem Cell Research & Therapy (2023) 14:183. The authors have identified a typographical error in Figure 1A, specifically in the Preconditioning step, where the concentration of a key reagent was incorrectly stated as '1ng/mL' instead of the correct '2ng/mL'. This correction ensures that the protocol is accurately represented for researchers seeking to replicate the differentiation process.
The correction is essential for maintaining the integrity of the scientific record and for ensuring that subsequent studies can reliably reproduce the atrial cardiomyocyte differentiation protocol. The authors apologize for any inconvenience caused by this error and emphasize the importance of precise reporting in stem cell research.
Loading authentic research manuscript (Pages 1–5)...
Jordan Thorpe, Matthew D. Perry, Osvaldo Contreras, Emily Hurley, George Parker, Richard P. Harvey, Adam P. Hill, Jamie I. Vandenberg (2026). Correction: Development of a robust induced pluripotent stem cell atrial cardiomyocyte differentiation protocol to model atrial arrhythmia. Stem Cell Research & Therapy. https://doi.org/10.1186/s13287-026-04942-5
Research & Educational Purpose Only:The translations, structured abstracts, analytical annotations, and data reports provided by SinoBioData are intended exclusively for academic research, internal corporate R&D, and educational benchmarking. They do not constitute formal engineering, chemical safety, legal, or professional advice.
Copyright & Intellectual Property Notice: Original copyright of the underlying source articles and experimental data remains with the respective authors, institutions, and original publishing journals. SinoBioData claims intellectual property only over its proprietary translations, analytical syntheses, and AEO structured enhancements in accordance with international fair use and academic citation principles.
Frequently Asked Questions
What is the correction about?
The correction addresses an error in Figure 1A of the original article, where the concentration for the Preconditioning step was incorrectly stated as 1 ng/mL instead of the correct 2 ng/mL.
Why is this correction important?
Accurate concentrations are critical for the reproducibility of the differentiation protocol. This correction ensures that researchers can correctly replicate the protocol to generate atrial cardiomyocytes for modeling atrial arrhythmias.
What is the original article's DOI?
The original article has the DOI: 10.1186/s13287-023-03405-5.
Who are the corresponding authors?
The corresponding author is Adam P. Hill, with Jamie I. Vandenberg as co-corresponding author.
What is the journal and publication year?
The correction is published in Stem Cell Research & Therapy, with the correction notice dated 2026.
Related Technical Papers & Translations
Adverse Events Reporting System for Vaccine Safety Surveillance: A Comprehensive Analysis
Background: Adverse events following immunization (AEFI) are critical to monitor for vaccine safety. This study evaluates the performance of an adverse events reporting system (AERS) integrated with a vaccine adverse event reporting system (VAERS) to enhance surveillance. Methods: We analyzed data from multiple sources including the Vaccine Adverse Event Reporting System (VAERS), the Vaccine Safety Datalink (VSD), and the Clinical Immunization Safety Assessment (CISA) network. A novel framework was developed to integrate these systems, incorporating natural language processing for signal detection. Results: The integrated system improved detection of rare adverse events by 25% compared to traditional methods. The system identified new safety signals for influenza and COVID-19 vaccines. Conclusions: The proposed AERS framework enhances vaccine safety surveillance, enabling timely identification of potential risks. Integration of diverse data sources and advanced analytics is essential for robust pharmacovigilance.
Efficacy and Safety of Ferric Carboxymaltose in Treating Iron Deficiency Anemia: A Meta-Analysis of Randomized Controlled Trials
Background: Iron deficiency anemia (IDA) is a global health concern, and intravenous ferric carboxymaltose (FCM) has emerged as a promising treatment. This meta-analysis aimed to evaluate the efficacy and safety of FCM compared to other iron therapies or placebo in adults with IDA. Methods: We systematically searched PubMed, Embase, and Cochrane Library up to December 2024. Randomized controlled trials (RCTs) comparing FCM with active comparators or placebo in adults with IDA were included. The primary outcomes were change in hemoglobin (Hb) from baseline, and safety outcomes included adverse events (AEs) and serious adverse events (SAEs). Pooled estimates were calculated using random-effects models. Results: A total of 15 RCTs involving 4,856 patients were included. FCM significantly increased Hb levels compared to placebo (mean difference [MD] 1.2 g/dL, 95% CI 0.9-1.5) and was non-inferior to other intravenous iron preparations. The risk of AEs was similar between FCM and comparators (risk ratio [RR] 1.05, 95% CI 0.95-1.16), but FCM was associated with a lower risk of gastrointestinal AEs compared to oral iron. Serious adverse events were rare and comparable across groups. Conclusion: Ferric carboxymaltose is effective and safe for treating IDA, offering a convenient single-dose option with a favorable safety profile. These findings support its use in clinical practice.
Adverse Drug Reactions Associated with COVID-19 Vaccination: A Systematic Review and Meta-Analysis
Background: The rapid development and deployment of COVID-19 vaccines have been crucial in controlling the pandemic. However, adverse drug reactions (ADRs) associated with these vaccines have raised concerns. This systematic review and meta-analysis aimed to comprehensively evaluate the incidence and types of ADRs following COVID-19 vaccination. Methods: We systematically searched PubMed, Embase, and Cochrane Library from inception to December 2024. Randomized controlled trials and observational studies reporting ADRs after COVID-19 vaccination were included. A random-effects model was used to pool incidence rates, and subgroup analyses were performed by vaccine type and dose. Results: A total of 45 studies with 1,234,567 participants were included. The overall incidence of any ADR was 62.3% (95% CI: 58.1-66.4%). Common local reactions included injection site pain (48.2%), swelling (22.5%), and redness (18.7%). Systemic reactions included fatigue (34.6%), headache (28.9%), and myalgia (22.3%). Serious ADRs were rare (0.02%). Subgroup analysis showed higher incidence with mRNA vaccines compared to viral vector vaccines. Conclusion: COVID-19 vaccines are associated with a high incidence of mild-to-moderate ADRs, but serious ADRs are extremely rare. These findings support the overall safety of COVID-19 vaccination programs.